×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RNAZ – transcode therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RNAZ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/22
08:39 am
rnaz
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors [Yahoo! Finance]
Medium
Report
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors [Yahoo! Finance]
12/22
08:01 am
rnaz
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
Medium
Report
TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors
12/11
08:05 am
rnaz
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
High
Report
TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial
11/17
08:41 am
rnaz
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer [Yahoo! Finance]
Low
Report
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer [Yahoo! Finance]
11/17
08:01 am
rnaz
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
Low
Report
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
10/25
12:13 pm
rnaz
TransCode Therapeutics (NASDAQ:RNAZ) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
TransCode Therapeutics (NASDAQ:RNAZ) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
10/14
08:42 am
rnaz
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO [Yahoo! Finance]
Low
Report
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO [Yahoo! Finance]
10/14
08:06 am
rnaz
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
High
Report
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/23
06:03 am
rnaz
Form EFFECT Transcode Therapeutics,
Neutral
Report
Form EFFECT Transcode Therapeutics,
12/22
04:40 pm
rnaz
Form 3 Transcode Therapeutics, For: Oct 06 Filed by: CZEREPAK ELIZABETH
Medium
Report
Form 3 Transcode Therapeutics, For: Oct 06 Filed by: CZEREPAK ELIZABETH
12/22
04:39 pm
rnaz
Form 3 Transcode Therapeutics, For: Dec 19 Filed by: STOVER JACK E
Medium
Report
Form 3 Transcode Therapeutics, For: Dec 19 Filed by: STOVER JACK E
12/22
08:13 am
rnaz
Form 8-K Transcode Therapeutics, For: Dec 19
Medium
Report
Form 8-K Transcode Therapeutics, For: Dec 19
12/12
04:17 pm
rnaz
Form S-3 Transcode Therapeutics,
Medium
Report
Form S-3 Transcode Therapeutics,
12/11
08:09 am
rnaz
Form 8-K Transcode Therapeutics, For: Dec 11
High
Report
Form 8-K Transcode Therapeutics, For: Dec 11
11/14
04:05 pm
rnaz
Form 10-Q Transcode Therapeutics, For: Sep 30
Low
Report
Form 10-Q Transcode Therapeutics, For: Sep 30
11/10
02:17 pm
rnaz
Form SCHEDULE 13G/A Transcode Therapeutics, Filed by: GOLDMAN SACHS GROUP INC
Neutral
Report
Form SCHEDULE 13G/A Transcode Therapeutics, Filed by: GOLDMAN SACHS GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: